131 related articles for article (PubMed ID: 15727931)
41. A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.
Saleem M; Adhami VM; Zhong W; Longley BJ; Lin CY; Dickson RB; Reagan-Shaw S; Jarrard DF; Mukhtar H
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):217-27. PubMed ID: 16492908
[TBL] [Abstract][Full Text] [Related]
42. A novel method of generating prostate cancer metastases from orthotopic implants.
Corey E; Quinn JE; Vessella RL
Prostate; 2003 Jul; 56(2):110-4. PubMed ID: 12746835
[TBL] [Abstract][Full Text] [Related]
43. Comparative gene and protein expression in primary cultures of epithelial cells from benign prostatic hyperplasia and prostate cancer.
Rose A; Xu Y; Chen Z; Fan Z; Stamey TA; McNeal JE; Caldwell M; Peehl DM
Cancer Lett; 2005 Sep; 227(2):213-22. PubMed ID: 16112424
[TBL] [Abstract][Full Text] [Related]
44. Metastasis suppressor gene Raf kinase inhibitor protein (RKIP) is a novel prognostic marker in prostate cancer.
Fu Z; Kitagawa Y; Shen R; Shah R; Mehra R; Rhodes D; Keller PJ; Mizokami A; Dunn R; Chinnaiyan AM; Yao Z; Keller ET
Prostate; 2006 Feb; 66(3):248-56. PubMed ID: 16175585
[TBL] [Abstract][Full Text] [Related]
45. [Preclinical models of prostate cancer].
Fizazi K; Navone NM
Bull Cancer; 2005 Feb; 92(2):129-41. PubMed ID: 15749642
[TBL] [Abstract][Full Text] [Related]
46. A novel serum marker, total prostate secretory protein of 94 amino acids, improves prostate cancer detection and helps identify high grade cancers at diagnosis.
Nam RK; Reeves JR; Toi A; Dulude H; Trachtenberg J; Emami M; Daigneault L; Panchal C; Sugar L; Jewett MA; Narod SA
J Urol; 2006 Apr; 175(4):1291-7. PubMed ID: 16515983
[TBL] [Abstract][Full Text] [Related]
47. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
48. Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.
Banach-Petrosky W; Jessen WJ; Ouyang X; Gao H; Rao J; Quinn J; Aronow BJ; Abate-Shen C
Cancer Res; 2007 Oct; 67(19):9089-96. PubMed ID: 17909013
[TBL] [Abstract][Full Text] [Related]
49. An investigation of the effects of late-onset dietary restriction on prostate cancer development in the TRAMP mouse.
Suttie AW; Dinse GE; Nyska A; Moser GJ; Goldsworthy TL; Maronpot RR
Toxicol Pathol; 2005; 33(3):386-97. PubMed ID: 15805078
[TBL] [Abstract][Full Text] [Related]
50. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
51. SIRT1 is significantly elevated in mouse and human prostate cancer.
Huffman DM; Grizzle WE; Bamman MM; Kim JS; Eltoum IA; Elgavish A; Nagy TR
Cancer Res; 2007 Jul; 67(14):6612-8. PubMed ID: 17638871
[TBL] [Abstract][Full Text] [Related]
52. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
53. Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.
Seligson DB; Hongo F; Huerta-Yepez S; Mizutani Y; Miki T; Yu H; Horvath S; Chia D; Goodglick L; Bonavida B
Clin Cancer Res; 2007 Oct; 13(20):6056-63. PubMed ID: 17947468
[TBL] [Abstract][Full Text] [Related]
54. Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three-dimensional power Doppler ultrasound.
Xuan JW; Bygrave M; Jiang H; Valiyeva F; Dunmore-Buyze J; Holdsworth DW; Izawa JI; Bauman G; Moussa M; Winter SF; Greenberg NM; Chin JL; Drangova M; Fenster A; Lacefield JC
Cancer Res; 2007 Mar; 67(6):2830-9. PubMed ID: 17363606
[TBL] [Abstract][Full Text] [Related]
55. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model.
Wirtzfeld LA; Wu G; Bygrave M; Yamasaki Y; Sakai H; Moussa M; Izawa JI; Downey DB; Greenberg NM; Fenster A; Xuan JW; Lacefield JC
Cancer Res; 2005 Jul; 65(14):6337-45. PubMed ID: 16024636
[TBL] [Abstract][Full Text] [Related]
56. Identification of prostate cancer-associated microRNAs in circulation using a mouse model of disease.
Selth LA; Townley SL; Gillis JL; Tilley WD; Butler LM
Methods Mol Biol; 2013; 1024():235-46. PubMed ID: 23719956
[TBL] [Abstract][Full Text] [Related]
57. Mouse models of prostate cancer.
Sharma P; Schreiber-Agus N
Oncogene; 1999 Sep; 18(38):5349-55. PubMed ID: 10498888
[TBL] [Abstract][Full Text] [Related]
58. Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model.
Nandana S; Ellwood-Yen K; Sawyers C; Wills M; Weidow B; Case T; Vasioukhin V; Matusik R
Prostate; 2010 May; 70(6):591-600. PubMed ID: 19938013
[TBL] [Abstract][Full Text] [Related]
59. Structural and molecular biology of PSP94: Its significance in prostate pathophysiology.
Anklesaria JH; Mhatre DR; Mahale SD
Front Biosci (Landmark Ed); 2018 Jan; 23(3):535-562. PubMed ID: 28930560
[TBL] [Abstract][Full Text] [Related]
60. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression.
FitzGerald LM; Zhang X; Kolb S; Kwon EM; Liew YC; Hurtado-Coll A; Knudsen BS; Ostrander EA; Stanford JL
Hum Mutat; 2013 Jan; 34(1):149-56. PubMed ID: 22887727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
